Click HERE for more resources Abstract: The increasing incidence of fatal opioid overdose is a public health crisis in Canada. While buprenorphine/naloxone and methadone are the standard…
Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.
VCH has new guidelines in place to help prescribers support people who use drugs (PWUD) who need assistance managing withdrawal symptoms due to COVID-19.
In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.
“We strongly encourage all partners to work to implement these exemptions in their jurisdictions
and welcome any additional suggestions you may have to maintain Canadians’ access to
controlled substances for medical reasons during the pandemic.”
Guidance from the Yale Program in Addiction Medicine